EY State of Sustainability 2022


As the implications of climate change only get more severe, improving sustainability and hitting our environmental objectives is becoming increasingly important. In this report, EY explores sustainability for businesses in Ireland.

 
Key takeaways include:
 
  • The recent IPCC Report has found that it is now ‘almost inevitable’ that temperatures will rise above 1.5C.
  • Factors which drive organisations to hit sustainability targets include the need to future-proof businesses and ensure compliance with terms of legislation.
  • 28% of respondents said their operations based in Ireland have adopted science-based targets to reach sustainability goals.

Share this with your Community





Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

Building an AI-Ready Workforce

AI is reshaping ways of working faster than most organisations can adapt, putting talent strategy at the top of the Board agenda. Criticaleye's Anna Mitchell asks Board Leaders and CPOs with hands-on experience o...


Richard Williams, Former CHRO at Western Union: How HR Becomes a Board-Level Power Function

Richard Williams, Board Mentor at Criticaleye and former Chief Human Resources Officer (CHRO) at Western Union joins Bridgette Hall, Senior Editor at Criticaleye to explore what it takes to lead HR in a global organi...


Click here to download this insight

VIEWPOINTS | The Sustainability Reset

There’s no doubt that the external narrative around sustainability has shifted over the last 18 months, but behind the scenes companies continue to navigate the challenges and opportunities associated with the ...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 210




NatWest Group Southern Water LACE Partners Drax Group plc London Stock Exchange Group Stream Global Payments E.ON UK NATS Rolls-Royce British Land Lightsource bp AlixPartners Aldermore Group Hitachi Solutions Legal & General Mayborn Group GlaxoSmithKline plc